Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.74 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074611 | 0.82 | DPP4 (0.80) | DPP4DPP7DPP8 | |
| SCHEMBL160102 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL15007469 | 0.82 | DPP4 (0.61) | DPP4DPP7DPP8 | |
| SCHEMBL29416829 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL220478 | 0.82 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL7242600 | 0.81 | DPP4 (0.67) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356224 | 0.81 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| SCHEMBL5512247 | 0.81 | DPP4 (0.60) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL299895 | 0.81 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356225 | 0.81 | DPP4 (0.98) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617340-B1 | Treating non-insulin-dependent diabetes mellitus | NOVARTIS AG (CH) | 2003-09-09 | — | — | US | claimed |
| US-20070123470-A1 | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue | MERCK & CO., INC. | 2007-05-31 | — | — | US | disclosed |
| US-6617340-B1 | Treating non-insulin-dependent diabetes mellitus | NOVARTIS AG (CH) | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123470-A1 | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue | DPP4, DPP3, GHSR | DPP4 1/4885DPP7 7/4885DPP8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.